FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
Completed
National Cancer Institute (NCI)
Phase 1
2002-09-01
This phase I trial is studying the side effects and best dose of FR901228 in treating
children with refractory or recurrent solid tumors or leukemia. Drugs used in chemotherapy
use different ways to stop cancer cells from dividing so they stop growing or die
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Completed
National Cancer Institute (NCI)
Phase 2
2003-05-01
This phase II trial is studying how well romidepsin works in treating patients with relapsed
or refractory acute myeloid leukemia. Drugs used in chemotherapy, such as romidepsin, work in
different ways to stop tumor cells from dividing so they stop growing or die.
FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
Terminated
National Cancer Institute (NCI)
Phase 2
2004-01-01
This phase I/II trial is studying the best dose of FR901228 when given together with
rituximab and fludarabine and to see how well FR901228 works alone in treating patients with
relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma. Drugs used in chemotherapy,
such as FR901228 and fludarabine, work in different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer
cells and either kill them or deliver cancer-killing substances to them without harming
normal cells. Rituximab may increase the effectiveness of chemotherapy drugs by making cancer
cells more sensitive to the drugs.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
